close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CNS Pharmaceuticals, Inc. - Common Stock (NQ:CNSP)

4.950 -0.060 (-1.20%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CNS Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
Study Suggests Testosterone Slows Glioblastoma Progression in Men
Via Investor Brand Network
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports First-Quarter 2026 Results, Advances Strategic Transformation
Via Investor Brand Network
News headline image
CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progress
Via ACCESS Newswire
Blocking Fructose Metabolism Boosts Immune Response to Childhood Cancer
Via Investor Brand Network
Immunologists Discover How Cancer Reprograms Immune Cells to Support Cancer Growth
Via Investor Brand Network
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Secures $22.5 Million Private Placement Financing
Via Investor Brand Network
News headline image
CNS Pharmaceuticals Announces Oversubscribed $22.5 Million Private Placement Financing
Via ACCESS Newswire
Study Finds Exercise, Ibuprofen Combat Brain Fog in Cancer Patients
Via Investor Brand Network
New Molecule May Open New Therapeutic Pathway Against Brain Cancer
Via Investor Brand Network
Why Molecular Testing is Increasingly Important in CNS Cancers
Via Investor Brand Network
Scientists Discover Brain Cells That Aid Brain Cancer Development
Via Investor Brand Network
Preclinical Study Reveals Promising Treatment for Glioblastoma
Via Investor Brand Network
Study Explores Whether a Common Vitamin Could Fight Brain Cancer
Via Investor Brand Network
Researchers Solve 50-Year-Old Challenge in Making Cancer Drug
Via Investor Brand Network
Researchers Discover Mechanism Behind Deadly Pediatric Brain Cancer
Via Investor Brand Network
Misinformation Could Thwart the Potential of Cancer Vaccines
Via Investor Brand Network
Fewer Men Undergo Cancer Screening, Study Shows
Via Investor Brand Network
Mirror-Image Amino Acid Shows Promise in Starving Cancer Cells
Via Investor Brand Network
Researchers Trace Differing Pediatric Brain Tumors to Common Source
Via Investor Brand Network
TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Launches New Growth Strategy Focused On Neurology And Oncology Pipeline Expansion
Via Investor Brand Network
News headline image
CNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology Pipeline
Via ACCESS Newswire
New Research Challenges Current Thinking on How Brain Cancer Develops
Via Investor Brand Network
New Treatment Dramatically Improves Survival for Patients with Deadly Brain Tumors
Via Investor Brand Network
TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Appoints Lynne Kelley as Chief Medical Officer
Via Investor Brand Network
New Study Unveils Promising Way to Conduct Brain Surgery Against Cancer
Via Investor Brand Network
News headline image
CNS Pharmaceuticals Appoints Lynne Kelley, MD, FACS, as Chief Medical Officer, Completing Executive Leadership Team
Via ACCESS Newswire
American Science Suffers as Brain Drain Intensifies
Via Investor Brand Network
Pressure from Brain Tumors Triggers Self-Destruct Mechanism in Neurons, Study Finds
Via Investor Brand Network
TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Appoints New Executive Leadership Team
Via Investor Brand Network
< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today